NASACORT ALLERGY 24 HOUR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NASACORT ALLERGY 24 HOUR (NASACORT ALLERGY 24 HOUR).
Corticosteroid; binds to glucocorticoid receptor, modulating gene expression to decrease pro-inflammatory cytokines, inhibit phospholipase A2, and reduce eosinophil activity.
| Metabolism | Hepatic via CYP3A4; active metabolite (21-deacetyltriamcinolone acetonide) is formed. |
| Excretion | Primarily fecal/biliary (approximately 70-80%) with less than 10% renal excretion of unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is approximately 3-4 hours, which supports twice-daily dosing for allergic rhinitis. |
| Protein binding | Approximately 80-90% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.0-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Intranasal: <1% (very low systemic bioavailability due to extensive first-pass metabolism and limited absorption). |
| Onset of Action | Intranasal: clinical effect observed within 12-24 hours after first dose, with full benefit typically after 3-5 days of regular use. |
| Duration of Action | Duration of action is approximately 24 hours, allowing once-daily dosing for maintenance of allergic rhinitis symptom control. |
| Molecular Weight | 434.5 |
Two sprays (55 mcg/spray) per nostril once daily; total daily dose 220 mcg.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment; pharmacokinetics unchanged. |
| Liver impairment | No dose adjustment required for hepatic impairment; safety and efficacy not studied in severe hepatic impairment. |
| Pediatric use | Ages 2-5 years: One spray (55 mcg) per nostril once daily. Ages 6-11 years: Two sprays (55 mcg) per nostril once daily. Ages 12 years and older: Same as adult. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased systemic sensitivity; monitor for adverse effects. |
| 1st trimester | Triamcinolone acetonide is a corticosteroid. Systemic absorption after intranasal use is low but not zero. Generally avoided unless benefit outweighs risk; associated with small increased risk of oral clefts in some studies. |
| 2nd trimester | Use with caution. Systemic corticosteroids may cause fetal growth restriction; intranasal route minimizes exposure. Reserve for conditions requiring treatment. |
| 3rd trimester | Use with caution. Prolonged use of high-dose systemic corticosteroids may suppress fetal adrenal function; intranasal form has low bioavailability. |
Clinical note
Comprehensive clinical and safety monograph for NASACORT ALLERGY 24 HOUR (NASACORT ALLERGY 24 HOUR).
| Placental transfer | Triamcinolone acetonide crosses the placenta. The extent is dose-dependent; after intranasal administration, systemic absorption is low (about 40-50% bioavailable), leading to low but measurable fetal exposure. Fetal concentrations are generally <10% of maternal concentrations after inhalation; intranasal data limited. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to triamcinolone acetonide or any excipientUntreated localized nasal infection (e.g., herpes simplex, bacterial, fungal)
| Precautions | Nasal septal perforation, Localized Candida infection, Immunosuppression, Adrenal suppression with excessive doses, Growth retardation in children, Increased intraocular pressure/glaucoma, Cataracts |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | Nasacort Allergy 24 Hour contains triamcinolone acetonide, a corticosteroid. It is for intranasal use only. Avoid contact with eyes. Onset of action is 12-24 hours; not for immediate relief. Monitor for epistaxis, nasal septal perforation, or immunosuppression with prolonged use. Use lowest effective dose in children to avoid growth suppression. |
Loading safety data…
| Triamcinolone acetonide is excreted into breast milk in small quantities after inhalation or systemic use; intranasal administration results in minimal systemic absorption and is unlikely to affect the infant. However, prolonged high-dose use should be avoided. Use lowest effective dose for shortest duration. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Insufficient human data; corticosteroids generally associated with increased risk of orofacial clefts (odds ratio 1.3-1.7) in animal studies. Second/third trimesters: Risk of fetal growth restriction, adrenal suppression. Avoid systemic exposure; intranasal use yields negligible systemic levels. |
| Fetal Monitoring | Monitor fetal growth (ultrasound if prolonged use). Assess maternal adrenal function if high doses or prolonged therapy. Observe neonate for adrenal suppression if used near term. |
| Fertility Effects | At therapeutic intranasal doses, no adverse effects on fertility. High systemic doses may impair spermatogenesis or ovarian function; intranasal route does not achieve such levels. |
| Patient Advice | Prime spray by pumping 5 times before first use or if not used for 2 weeks. · Use regularly; not for acute symptom relief. · Avoid spraying directly onto nasal septum. · Clean nozzle with warm water after each use. · Report persistent nosebleeds or signs of infection. |